Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Research
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. To advance oncolytic virotherapy research, Creative Biolabs has built an oncolytic virus engineering platform, and updated the list of oncolytic virus products, which are of high-quality and are ready-to-transfect.
- New York, NY (1888PressRelease) May 28, 2021 - As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and kill tumor cells. Up to now, two OV drugs have been marketed globally, and many more are still in the research and development stage.
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs has integrated a package of premade OV products, covering the most researched type of genetically-engineered adenovirus (AdV), vesicular stomatitis virus (VSV), herpes simplex virus (HSV), and vaccinia virus (VACV), to facilitate related research on treatment of melanoma, prostate cancer, breast cancer, ovarian cancer, and others.
· Reporter-encoding Oncolytic Virus
Reporter-encoding oncolytic viruses allow accurate tracking of gene expression, tumor metastases, viral infection, and assessment of gene therapy. Creative Biolabs has released a series of purified reporter-encoding OVs, including herpes simplex virus and vaccinia virus.
Featured products:
Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), SV40-GFP
Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-Dsred
Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-luciferase
· Cytokine-expressing Oncolytic Virus
Research has shown that the oncolytic efficacy of OVs can be enhanced through the expression of therapeutic transgenes like cytokines. Creative Biolabs has built an advanced OV engineering platform which provides a series of purified cytokine-expressing OV products.
Featured products:
Cytokine-expressing Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-IL-15
Cytokine-expressing Oncolytic Vaccinia Virus Western Reserve (ΔE3L), pSE/L-mLIGHT
Cytokine-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-CCL17
Besides, the product portfolio also ranges from immune checkpoint antibody-armed OVs, capsid-modified OVs, miRNA-regulated OVs to oncolytic adenovirus construction kits. Creative Biolabs ensures accurate design and construction, and manifold functional validations, and if there are any specific demands, the scientist team will help design customized products with timely delivery.
Detailed information about OV-related services, and products at Creative Biolabs can be found on https://www.creative-biolabs.com/oncolytic-virus.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services to support novel therapeutics development. The whole pipeline covers oncolytic virus engineering, construction, in vitro validation study, in vivo preclinical study, disease-specific oncolytic virotherapy development, and oncolytic virotherapy development for combination therapy with cancer immunotherapy.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam